Cidara Therapeutics Inc represents values and a corporate philosophy focused on addressing unmet medical needs through innovative anti-infective therapies. The company is dedicated to developing novel treatments for serious infections, particularly caused by multi-drug resistant pathogens. Cidara Therapeutics Inc strives to bring advancements in science and healthcare by utilizing its proprietary Cloudbreak™ platform, which enables the discovery and development of potent antifungal and antibacterial compounds. With a commitment to patient health, scientific excellence, and collaboration, Cidara Therapeutics Inc aims to make a lasting impact in the field of infectious diseases.

Cidara Therapeutics Inc is primarily present in the United States.

Cidara Therapeutics Inc has achieved several significant milestones. One of the notable accomplishments was the successful completion of Phase 2 clinical trials for its lead antifungal candidate, rezafungin acetate, demonstrating its efficacy in treating invasive Candida infections. Additionally, the company received Qualified Infectious Disease Product (QIDP) designation from the FDA, which provides incentives for the development of innovative antibiotics. Cidara Therapeutics Inc also expanded its pipeline by entering into collaborations with leading pharmaceutical companies. These milestones highlight the company's dedication to advancing novel therapies for serious fungal infections, solidifying its position as a promising player in the biopharmaceutical industry.

Cidara Therapeutics Inc is a biotechnology company that focuses on developing novel anti-infectives. Founded in 2014, the company is headquartered in San Diego, California. Cidara Therapeutics is dedicated to addressing unmet medical needs in fungal and bacterial infections, particularly those resistant to current therapies. They utilize their proprietary Cloudbreak® Immunotherapy Platform to develop and commercialize innovative treatments. With a team of experienced scientists and a strong pipeline of potential therapies, Cidara Therapeutics is aiming to revolutionize the treatment landscape for infectious diseases. The company continues to collaborate with pharmaceutical partners and research institutions to advance its mission of improving patient outcomes.

The main competitors of Cidara Therapeutics Inc in the market include pharmaceutical companies such as Pfizer, Merck & Co., Inc., and GlaxoSmithKline plc. These companies also operate in the field of developing and commercializing innovative therapeutics. Each company competes to bring novel treatments and therapies to market, aiming to address unmet medical needs. As Cidara Therapeutics Inc strives to advance its portfolio of antifungal and antibacterial products, it faces competition from well-established industry leaders in the pharmaceutical sector.

Cidara Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Cidara Therapeutics Inc's business model focuses on developing novel anti-infectives to address serious unmet medical needs. The company utilizes its proprietary Cloudbreak® platform to design and develop innovative therapeutics that target infections caused by multidrug-resistant pathogens. By leveraging its expertise in immunology and chemogenomics, Cidara aims to provide effective solutions for patients with life-threatening diseases. Through strategic partnerships and collaborations, the company aims to advance its pipeline and commercialize its products globally, aiming to improve patient outcomes and address the growing global threat of antimicrobial resistance.

Το Cidara Therapeutics P/E είναι -0,32.

Το KUV της εταιρείας Cidara Therapeutics είναι 5,79.

Το AlleAktien Qualitätsscore για το Cidara Therapeutics είναι 6/10.

Ο κύκλος εργασιών του αναμενόμενη Cidara Therapeutics είναι 10,20 Εκ. USD.

Το αναμενόμενη Cidara Therapeutics κέρδος είναι -186,63 Εκ. USD.

Cidara Therapeutics, Inc. is a biopharmaceutical company focused on developing therapy options for difficult-to-treat infectious diseases. With the goal of helping patients with life-threatening conditions, the company is working on developing innovative treatment methods with a focus on immunotherapy and antifungal drugs. The business model of Cidara Therapeutics is based on a diversified product pipeline consisting of two main divisions: antifungal platforms and immunotherapy platforms. The antifungal platforms are being developed to create broad-spectrum antifungal drugs that enable the treatment of drug-resistant fungal infections. The immunotherapy platforms are being developed to create groundbreaking immunosuppressants that enhance the body's natural defense against diseases. A core product of the company is "Rezafungin Acetate," an intravenous antifungal drug developed for serious fungal infections such as Candida glabrata. The drug is currently in late-stage clinical phase III in the USA. Cidara has also developed a broad-spectrum antifungal drug called "CD101," which is currently undergoing clinical trials. Cidara Therapeutics is also developing immunotherapy platforms that can provide potential therapies for diseases such as cancer and autoimmune diseases. The company specializes in natural killer cells and is working on NK cell therapeutics to support the immune system in serious diseases such as cancer. The company utilizes a variety of partnerships and financial support to develop its product pipeline. In January 2020, Cidara announced a strategic collaboration with Janssen Pharmaceuticals to further the development and commercialization of CD101A in certain geographic regions. Another important aspect of Cidara Therapeutics' business model is the use of continuous innovation and technology platforms to improve the effectiveness and availability of medications. The company utilizes proprietary technology platforms such as "Cloudbreak" and "ImmunoSTAT" to enhance the development of new therapies through the identification of novel cell types and mechanisms. In conclusion, Cidara Therapeutics is an innovative biopharmaceutical company specializing in a dual-track product pipeline consisting of antifungal platforms and immunotherapy platforms. With a wide range of products targeting life-threatening diseases, Cidara utilizes partnerships and innovation to implement its vision of better healthcare. Answer: Cidara Therapeutics, Inc. is a biopharmaceutical company focused on developing therapy options for difficult-to-treat infectious diseases.

Η Cidara Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Cidara Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Cidara Therapeutics είναι US1717571079.

Το WKN της Cidara Therapeutics είναι A14R2R.

Ο τίκερ της Cidara Therapeutics είναι CDTX.

Κατά τους τελευταίους 12 μήνες η Cidara Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Cidara Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Cidara Therapeutics ανέρχεται σήμερα στο .

Cidara Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Cidara Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Cidara Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Cidara Therapeutics από την 10/11/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 10/11/2024.

Η τελευταία μερίσματος έγινε στις 10/11/2024.

Το έτος 2023, η Cidara Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Cidara Therapeutics καταβάλλονται σε USD.